Dispatch

Dispatch

Overview

About Dispatch

Simplify's Rating
Why Dispatch is rated
C+
Rated B on Competitive Edge
Rated B on Growth Potential
Rated D+ on Differentiation

Industries

Data & Analytics

Enterprise Software

AI & Machine Learning

Financial Services

Company Size

1-10

Company Stage

Series A

Total Funding

$32.9M

Headquarters

Miami, Florida

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Schwab praises Dispatch as early adopter of Digital Account Onboarding API.
  • Raised $18M Series A to enhance data orchestration for advisors.
  • 90% reduction in NIGO rejections via AI-powered data validation.

What critics are saying

  • Schwab delays Q1 2026 API rollout, crippling Dispatch's onboarding.
  • Fidelity and Pershing launch competing native API integrations within 6-12 months.
  • Dispatch Bio's $216M raise confuses investors, diverting wealthtech funding.

What makes Dispatch unique

  • Dispatch automates Schwab account onboarding via API in minutes.
  • Supports 99% of account types including SMAs and TAMPs across custodians.
  • Bi-directional syncing eliminates manual data entry across CRMs and tools.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$32.9M

Above

Industry Average

Funded Over

4 Rounds

Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Above Average

Industry standards

$15M
$8.2M
Discord
$15M
Canva
$18M
Dispatch
$30M
Kalshi

Benefits

Health Insurance

Vision Insurance

Dental Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Parental Leave

Stock Options

Company News

Business Wire
Feb 11th, 2026
Dispatch unveils API for automated Schwab account onboarding in minutes

Dispatch, a data orchestration platform for wealth management, has announced development of an automated Schwab account onboarding API integration. The technology will enable advisors to open Schwab accounts in minutes directly from Dispatch, eliminating manual login requirements and multi-day processing times associated with DocuSign-based methods. The integration allows firms to send data directly from their CRM into Schwab Advisor Center, avoiding manual re-entry and reducing Not-In-Good-Order errors. Dispatch becomes one of the first platforms to support end-to-end Schwab digital account opening natively within their system. The solution addresses what firms identify as a major operational challenge, where advisors repeatedly enter data across multiple systems whilst clients wait weeks for fund transfers. Dispatch's enhanced account opening workflows are scheduled for rollout to Early Access clients in Q1 2026.

FinSMEs
Sep 5th, 2025
Dispatch Raises $18M in Series A Funding

Dispatch, a Miami, FL-based wealthtech solution provider enabling effortless client data management, raised $18M Series A funding

Axios
Sep 4th, 2025
Dispatch raises $18M for data software

Dispatch has raised $18 million in Series A funding to enhance data orchestration software for financial advisory firms, as reported by CEO Rob Nance to Axios.

Oncology Pipeline
Jul 23rd, 2025
Dispatch Bio raises $213m for Car-T.

Dr. Carl June, co-founder of Dispatch Bio, has emerged from stealth mode, adding $100 million to a 2023 $113 million Series A raise. Dispatch Bio is exploring a novel approach using a virus to deliver an antigen to tumor cells, followed by a Car-T therapy. The specifics remain undisclosed, but it may involve oncolytic viruses. June's previous ventures include Capstan Therapeutics, sold to AbbVie for $2 billion, and Tmunity, sold to Gilead in 2022.

BioPharma Dive
Jul 23rd, 2025
Dispatch raises $216M for universal tumor therapy

Dispatch Bio, a biotech startup formed in 2022, has raised $216 million to develop a universal solid tumor therapy. The company combines gene, cell, and immunotherapy to target tough-to-treat tumors. Dispatch's approach uses an engineered virus to tag cancer cells with an antigen, attracting CAR-T cells to destroy them. The company plans to start clinical testing next year and is backed by Arch Venture Partners, the Parker Institute, Bristol Myers Squibb, and others.

Recently Posted Jobs

Sign up to get curated job recommendations

Dispatch is Hiring for 4 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →